Page 88 - Portuguese Journal - SPORL - Vol 61. Nº1

Evaluated Study or Intervention Group Placebo Group Mean Difference;
Parameter Subgroup Mean, IV, Random,
Mean Standard Total Mean Standard Total 95% CI
Deviation Participants Deviation Participants
BENRALIZUMAB
NCT03450083 (b) -19.2 2.6 12 -14.6 20.1 12 -4.60 [-16.07,6.87]
OSTRO (b) -15.1 33.55 207 -7.9 33.22 203 -7.20 [-13.66,-0.74]
SNOT-22 Total (95% CI) 219 215 -6.57 [-12.20,0.94]

Heterogeneity: Tau =0.00; Chi =0.15, df=1 (P=0,.70); I =0%
2
2
2
Test for overall effect: Z=2.29 (P=0,.02)
NCT03450083 (b) -0.9 0.2 12 -0.3 0.3 12 -0.60 [-0.80,-0.40]
OSTRO (b) -0.22 1.76 207 0.18 1.44 203 -0.40 [-0.71,-0.09]
NPS Total (95% CI) 219 215 -0.54 [-0.72,-0.35]
Heterogeneity: Tau =0.00; Chi =1.11, df=1 (P=0,.29); I =10%
2
2
2
Test for overall effect: Z=5.74 (P<0,.00001)
NCT03450083 (b,c) -4.2 2.69 12 -1.6 2.94 12 -2.60 [-4.85,-0.35]
Lund Mackay OSTRO (b) -0.93 5.06 207 -0.2 4.2 203 -0.73 [-1.63,0.17]
Score Total (95% CI) 219 215 -1.37 [-3.10,0.37]
Heterogeneity: Tau =0.98; Chi =2.28, df=1 (P=0,.13); I =56%
2
2
2
Test for overall effect: Z=1.54 (P=0,.12)
SNOT-22 – Sinonasal Outcome Test-22; NPS – Nasal Polyp Score
IV –Inverse Variance
IC – Confidence Interval
(a) 16 weeks of follow-up;
(b) Change in the baseline;
(c) Standard deviation calculated from the standard error;
(d) Standard deviation calculated from the p-value;
(e) Standard deviation calculated from the confidence interval;

88 Portuguese Journal of Otorhinolaryngology - Head and Neck Surgery